Senolytics: Taking Out the Cellular Trash

One of the more interesting areas of longevity research involves something called cellular senescence.

As we age, some cells become damaged, stop functioning normally, and enter a state known as senescence. These cells are often referred to as “zombie cells” because they don’t die when they should, yet they no longer contribute positively to the tissues around them.

The problem is that senescent cells don’t simply sit quietly. They release inflammatory signals and other compounds that may negatively affect neighboring healthy cells. Researchers have linked the accumulation of senescent cells to many aspects of aging, including inflammation, reduced tissue repair, frailty, and age-related disease.

The body’s natural systems remove many of these cells, but that process appears to become less efficient with age.

My Approach

One strategy that has emerged from the longevity field is the use of senolytics – compounds intended to help identify and eliminate senescent cells.

Several years ago, Dr. Alan Green prescribed a senolytic protocol that included Dasatinib, a medication originally developed for leukemia treatment. The concept was not daily use, but rather occasional “housekeeping” sessions intended to help clear accumulated senescent cells.

I continue to incorporate a modified version of that protocol on a quarterly basis, although at significantly lower doses than when I first began. It’s a very potent drug and likely very difficult to find a doctor who will prescribe it for this purpose.

My Experience

I’ll be honest: Dasatinib is one of the few things I’ve taken that truly let me know it was there.

The original protocol hit me hard. Fatigue, headache, and a general feeling of being unwell were difficult to ignore. On second attempt, I substantially reduced the dosage to improve tolerability while still maintaining what I consider a periodic senolytic strategy.

Whether these protocols ultimately prove beneficial in humans remains an active area of research. Most of the strongest evidence today comes from animal studies, where senolytic therapies have produced impressive results in certain models of aging and disease.

Why I Continue

I view senolytics as one of several experimental longevity tools that show promise but remain far from settled science.

The idea makes intuitive sense to me: if aging tissues gradually accumulate dysfunctional cells, periodic cellular housekeeping may eventually prove beneficial.

For now, I continue to follow the research closely, use a conservative approach, and view this as one component of a broader strategy that includes exercise, nutrition, sleep, inflammation control, metabolic health, and cognitive engagement.

Common Senolytic Protocols

The most widely discussed senolytic protocol in the longevity community combines Dasatinib with Quercetin, often referred to as the D+Q protocol which was developed by Mayo Clinic.

Dasatinib was originally developed as a cancer medication, while Quercetin is a naturally occurring flavonoid found in many fruits and vegetables. Together, they have demonstrated senolytic activity in several animal studies and early human research.

Another popular senolytic compound is Fisetin, a plant flavonoid found naturally in strawberries and other fruits. Fisetin has attracted considerable interest because it appears to possess senolytic properties without requiring a prescription medication.

Commonly discussed approaches include:

D + Q Protocol

• Dasatinib (prescription)
• Quercetin
• Typically administered intermittently rather than continuously

Fisetin Protocol

• Fisetin
• Often combined with Quercetin
• Typically used for a few consecutive days each month or quarter

Because senolytic therapies are intended to clear accumulated senescent cells rather than produce an ongoing drug effect, most protocols use intermittent “hit-and-run” dosing and not daily administration.

What I Do

Under the guidance of Dr. Alan Green, I initially used a Dasatinib-based senolytic protocol. Over time, I significantly reduced the dosage because I found it difficult to tolerate.

Today, I continue a modified senolytic approach on a quarterly basis that includes:

• Low-dose Dasatinib
• Quercetin
• Fisetin

I view this as periodic cellular housekeeping rather than a daily intervention.

Important Note

Senolytic therapies remain an emerging area of longevity research. While the animal data are compelling and early human studies are encouraging, many questions remain regarding optimal compounds, dosing schedules, long-term safety, and effectiveness in healthy aging populations.

My Takeaway

If healthy aging is partly about preserving function, then removing dysfunctional cells may eventually become an important piece of the puzzle.

Whether senolytics ultimately become a standard part of preventive medicine remains to be seen. For now, I view them as an intriguing area of longevity research — one that I continue to watch with great interest while recognizing that many questions remain unanswered.

In case you missed my Substack article, you can read it here.